SOHM Inc (PK) (SHMN) Quote

Website is back up. No changes

Website completely down now, at least there's some action...lol...

Error establishing a database connection

who's running the company from India MP ?

I will never invest in a company again run by people from India, just never ends well.

Sohm sucks......sorry in advance for hurting any feelings

That L2 is on fire... not...

judging by L2 today I'd say someone expects News....

or hoping...

Anyone that didn't expect it hasn't been paying attention, it was disclosed in the PR.

https://www.globenewswire.com/en/news-release/2023/09/26/2749662/0/en/SOHM-Announces-Its-Acquisition-of-ABBIE-a-World-Class-Gene-Editing-Platform-Which-Can-Deliver-Genetic-Payloads-Using-Non-Viral-Vectors.html

With a one year restriction I'm not concerned with the shares he gets, long before his shares can be sold we will all know whether ABBIE is a success, if it is the pps will soar, if it isn't the pps will take a beating. Sounds simple I know but it's how I look at it.

He has to make some sales, license deals whatever in the 3rd qtr, or 4th but I hope it doesn't come to that. Then he has to keep the pps up and the co thriving.

Good luck to everyone !

It is good to know that the person who appears to be piloting the plane has an incentive to make sure it lands. The dilution isn't great, but I think we all expected it. Better to a control person than one of those bottom feeder convertible note lenders.

There isn't much detail around the ramifications of breach/termination, but I would hope that it is sufficiently convoluted that there is also incentive to work through any shortcomings rather than declare breach and walk away with the patents. If nothing else, the fact that Aguilar is a control person would make any attempt to call the deal a failure look enough like self dealing to make that outcome unlikely.

Really, we're looking forward to Q3 fins based on the timetable they've set forth. As it sounds like nominal activity outside of ABBIE, we probably won't see anything substantive until then (assuming they can keep to the proposed timetable)

Updated Question…How are we doing. Other then tweets do we have anything to look forward to?

Aguilar is going to wind up with around 3 billion shares if SHMN can fulfill their part of the deal They have to pay 3 million in cash as well. Due in the fall. Tick tock.

Hey JD, hows it feel being in the same boat with Dr Auguilar now ?

Granted he has a bigger seat, so far 300 ml reasons to move this stock North, way North.

As we all know, or most know, those shrs he just acquired are worthless at the current pps, all but impossible to unload once the legend is removed ( one year )

This is a very interesting scenario now, having management with some heavy skin in the game was lacking here for some time, just sit back and let the Dr do the rowing !

lol...

lol...and the higher it goes the less shares will be issued....

man get a life...

The lower the price goes, the more restricted shares that will have to issued for the ABBIE payoff.

over 4 ml dumped at .0009, keep those low bids in...

That tranche of shares was worth approximately $300k of the $3 million restricted shares owed. 9 more to go at these prices

SOHM, Inc.
@sohminc
We hereby share that, in accordance with the terms of the August of 2023 agreement between the two firms (SOHM and CGA369), the company has issued restricted stocks to CGA369 Intellectual Holdings, Inc. towards acquisition of ABBIE Technology/Intellectual Properties. At the time, a press release was released the acquisition details.

The business is operating as usual, releasing ABBIE kits in the third quarter, generating revenue, Manufacturing, etc.

$SHMN
7:30 PM · Jun 19, 2024

We hereby share that, in accordance with the terms of the August of 2023 agreement between the two firms (SOHM and CGA369), the company has issued restricted stocks to CGA369 Intellectual Holdings, Inc. towards acquisition of ABBIE Technology/Intellectual Properties. At the time,…— SOHM, Inc. (@sohminc) June 19, 2024

so many questions, why not call them and ask ?

According to SHMN's PR about the ABBIE acquisition:

ABBIE was acquired from CGA 369 for $10 million. The first payment of $6 million will be paid in 12 months from the effective date and will be a combination of $3 million cash and $3 million in restricted common stock. The remaining $4 million payment to CGA 369 will be triggered by ABBIE’s first $50 million of commercial sales.

3 million of restricted common stock would be 3 billion shares at the current share price.

Where is SHMN going to get the money for the 3 million in cash? Are they using most of the "up to 5 million" in financing? We know they aren't selling anything from the financials (of any appreciable worth). They aren't manufacturing anything.

Just AI generated tweets and pie in the sky projections that never come true.

you haven't read the contract....

maybe, just maybe they are hiring a high profile CEO..

along with a replacement for Rushing, they had to know Rushing was leaving weeks ago imo...

one year restriction on the shares, that much we do know..

Any new shares that SHMN issues will be restricted unless/until they file a new registration statement (S/1, S/8, etc.)

Yep, appears they are Restricted.

Held at DTC is unchanged.

https://www.otcmarkets.com/stock/SHMN/security

___
HL.

Outstanding shares increased.

SHMN ? Pink Current

🔑 AS:3.00B ? OS:1.91B ? R:639.29M ? UR:1.27B ? DTC:1.26B

✨ Outstanding Shares Updated:
- 🔴 From: 1,600,576,407 (1.60B)
- 🟢 To: 1,910,576,407 (1.91B - 6/18/2024)
(Diff: 310.00M, % Change: 19.368%)

Aguilar and ABBIE will leave if SHMN can't pay the millions promised for it in a few months. Breach of contract

SHMN was lucky to have him as long as they did imo......

we don't get to see the behind the scenes day by day, hopefully he made a difference going forward, I won't comment on his impact on the labs, one has to wonder what is going on with SD, so far it's been very disappointing.

Thanks. Actually he used to work at Quidel full-time back in 2013-2019.

So now he's back there doing some contract work for them. His work for Sohm has no doubt been invaluable. It's like you've said before too, we all know what we're waiting for, and in my opinion, it's going to be big green candles at some point. :)

https://www.linkedin.com/in/wm-dewey-rushing-7505a95/details/experience/

hL

great DD hl, thanks....

not sure what you read that made you assume it was an " unfriendly " departure...

and this comment, is it a joke ?

Don't see Aguilar leaving with out taking ABBIE with him.

He has now moved on to QuidelOrtho. He apparently fulfilled his tasks for Sohm, but according to his LinkedIn, he has been doing double duty for them since March 2023, and he left Sohm as of this month. He's always been an Independent guy, probably makes good money as a contractor/consultant.

Sad to see him go, but I appreciate your balanced comments. Hoping everyone still involved has learned a thing or two from him that can be continued, and if he needs replaced, they do it soon. According to their Tweet, they are still building their team, so maybe Aguilar already is in the middle of that process. Maybe we'll see an announcement at some point.

https://www.linkedin.com/in/wm-dewey-rushing-7505a95/

https://www.linkedin.com/company/quidelortho/

HL. Upsart Biotech at .0011.

Certainly does appear like a unfriendly departure.

SOHM, Inc.
@sohminc
Today we announce that Mr. Dewey Rushing's resignation has been accepted and relieved from his consulting assignment and as a VP-Quality with immediate effects. We are continuing to build our quality team to match our expected growth and vision.

But you know it could be as simple as a difference of Dewey thought he was worth X amount of dollars and Barry thought otherwise.

Don't see Aguilar leaving with out taking ABBIE with him.

But you are correct the wrong officer resigned.

Really doesn't matter , if there is any real money that going to be made here it is with ABBIE not the other part of the business.

$SHMN: Sad...But Reality setting in here (for me too)!

1. Dewey resignation is a harbinger of things to come!
The man is a Consummate Professional (& simply couldn't have been Fired....WHY? B/C there's NOTHING for him to do)!

2. There are NO Pharma MFG lines, nor Two 'F'-KNG Facilities! Prove it Barron! Upload AUTHENTIC VIDEOS!

3. Who's next? Aguilar or Gallegos ? ...(& the other two Nobody knows WTF they're upto )!.

4. Aguilar is putting his signature on Barry's BS Tweets & PRs.
He'll be in a lot of trouble, when looking for work in Biotech Bay / Silicon Valley.
You can bet on that!

5. Even if this was ONLY about ABBIE Kits....the company needs a certified Q/A V.P. or Dir on employ.
So ABBIE kits shipping in Q3 is HIGHLY UNLIKELY W/0 any Quality Control.
Unless they're outsourcing Q/A (Which will take a couple of months to get the Metrics ironed out)!

So best case Q4-Q1-2025
And the "Thousands of ABBIE Kits & $M'". ..
If TRUE....Q3-2025 -Q4 2025!

Get Barron FIRED! ASAP to SAVE this Co!

Today we announce that Mr. Dewey Rushing's resignation has been accepted and relieved from his consulting assignment and as a VP-Quality with immediate effects. We are continuing to build our quality team to match our expected growth and vision.— SOHM, Inc. (@sohminc) June 17, 2024


Bummer.

HL. Baby pharma, upstart biotech at .0011. $shmn

Yes! Merge with NVDA

they only need one thing now, and we all know what that is....

They have nothing but tweets.. and 50k Qs

This is an excellent example of how a coherent media strategy can drive interest and volume, if not necessarily PPS (at least, not immediately).

Given that this ticker frequently goes days at a time with no to nominal shares traded, a "significant" bump in share price from a $100 trade is meaningless when there is no follow-up...nobody can capitalize on it. IMHO, we need volume first, PPS second. Putting out good news without bullshit revenue projections that the market immediately discounts goes a long way toward that goal.

Bravo, SHMN. Bravo.

sure does knife...

SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-cell immunotherapy from a Healthy Human Donor

CHINO HILLS, CA / ACCESSWIRE / June 10, 2024 / SOHM, Inc. (OTC PINK:SHMN) (the "Company"), a pharmaceutical and upstart biotechnology company that manufactures and markets generic drugs covering numerous treatment categories, announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego. This type of engineered T -Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This breakthrough method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of virus and is able to engineer lung cancer cell killing CAR T-cells very efficiently. "The preliminary data is intriguing and suggests ABBIE can be used as a powerful tool in the development of immunotherapies."-David Aguilar Ph.D. COO SOHM Inc.

Dr. Aguilar, further stated that, CAR T-cell therapy is a groundbreaking form of cancer treatment that harnesses the power of a patient's own immune system to target and destroy cancer cells. Chimeric antigen receptor (CAR) T-cells are engineered patient immune cells that are designed to recognize and attack specific proteins on the surface of cancer cells.

The importance of CAR T-cell therapy lies in its ability to provide targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options.

The field of CAR T-cell therapy has seen significant growth and advancement in recent years, with several CAR T-cell therapies receiving approval from regulatory agencies for the treatment of certain types of blood cancers, such as leukemia and lymphoma. These approvals have paved the way for further research and development in the field, leading to the exploration of CAR T-cell therapy for other types of cancer.

In addition to its potential to revolutionize cancer treatment, CAR T-cell therapy also holds promise for the treatment of other diseases, such as autoimmune disorders, neurological disease and infectious diseases. As researchers continue to refine and optimize CAR T-cell therapy, the field is expected to continue to grow and expand, offering new hope for patients battling cancer and other serious illnesses.

On average, CAR T-cell therapy can cost anywhere from $373,000 to $475,000 per patient in the United States. This high cost is primarily due to the complex and personalized nature of CAR T-cell therapy, which involves the extraction, modification, and re-infusion of a patient's own immune cells.

In terms of the market value for CAR T companies, According to Vision Research Reports, the global cancer immunotherapy market size was estimated at USD 125.73 billion in 2023 and it is projected to increase USD 280.11 billion by 2033 with a CAGR of 8.34% from 2024 to 2033. Some of the key players in the CAR T-cell therapy market include Novartis, Gilead Sciences (through its acquisition of Kite Pharma), and Bristol Myers Squibb (through its acquisition of Celgene).

Overall, the market value for CAR T companies is expected to continue to grow as more research and development efforts are focused on advancing CAR T-cell therapy and expanding its application to a wider range of cancer types and other diseases. The high cost of CAR T-cell therapy presents challenges in terms of access and affordability, but ongoing efforts are being made to address these issues and make this innovative treatment more widely available to patients in need. More effective production methods via use of techniques like ABBIE genome editing will assist in bringing patient costs down and expanding use of the therapy to many more people affected by cancers.

We are proud to announce ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. ABBIE has the potential to revolutionize genome editing by allowing precise and targeted integration of predesigned donor DNA into the genome of cells. This groundbreaking technology opens up new possibilities for treating genetic diseases, developing novel therapies, and advancing scientific research. With its advanced targeting system, simplified operational protocols, and reduced risk of off-target effects, ABBIE could well become the gold standard for genetic modifications, paving the way for new discoveries and treatments said David Aguilar, COO of SOHM, Inc.

For more information about SOHM Inc. and its work on ABBIE, please visit www.SOHM.com

https://www.accesswire.com/873681/sohm-inc-announces-its-abbie-genome-editing-technology-successfully-engineered-a-t-cell-immunotherapy-from-a-healthy-human-donor

News out, looks promising.

https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Announces-its-ABBIE-Genome-Editing-Technology-Successfully-Engineered-a-T-cell-immunotherapy-from-a-Healthy-Hum?id=443403

All the best,

Knife

A million in Q3.... LOL

Booked is a cop out. There is no way to know if they actually have that. They've had other big orders "booked" before and nothing happened in the financials.

They are going to have to produce, market, and sell alot of kits in a short amount of time for revenues to jump in any meaningful way. Where are the resources to do that?

Another huge advantage CRISPR has over alternative gene-editing techniques is its expense. While previous techniques might cost a laboratory upward of $500 to edit a single gene, a CRISPR kit can do the same thing for under $100.

I've bought more than a few shares!!! Lol

always with the negative spin, yes, most of us know that the 4th qtr comes out with the annual due 3/31.

here's an alternative spin if you will, they most likely are making kits as we speak, imo all they need to do is announce orders booked in q3, along with shipping lets say at least a million in rev, booked in q3. personally I would expect much more but not fully knowing the cost of the kits we would all be guessing.

Then we have the Licensing deals that could hit at any time, along with this..

The company has other types of kits and related products in development.

https://www.globenewswire.com/news-release/2024/05/22/2886768/0/en/SOHM-Inc-Targets-Revolutionary-New-ABBIE-Genome-Editing-Kits-for-Q3-2024.html

so bash away....

June 4th. 2024. How are we looking?

If what they say is true, Q3 starts in less than a month. They'd have to make these kits in some kind of quantity, market them, and get them shipped out. So realistically, it would be Q4 before they'd hit the financials, which puts all the way until April.

Maybe one of their two manufacturing facilities can produce something more than dust. The San Diego one has been getting ramped up for over a year now.

buy a few kits Mike and get the ball rolling !!!!!!

lol...

it's hard to tell what he meant, including Dec 15th.....

what is truely pathetic is when a post like that goes without push back by the so called shareholders here, and correction by the author.

and not the first time..

I agree with your thoughts here JD, and as I have said all along ABBIE doesn't " feel " like anything they have bombed on before, at least to me. I think you know what I mean...

It kinda feels like their last opportunity to restore investor confidence.

Very fair...I can't argue with that...